Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 02:18 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Open-label Study to Investigate the Safety, Tolerability, PK, and Pharmacodynamics of the AKT Inhibitor GSK690693
NCT00493818 · GlaxoSmithKline · PHASE1 · terminated · last registry update 2017-01-18 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
No reason was published
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | The registry record gives no reason | – | Registry record, GlaxoSmithKline |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against AKT2 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2017-11-09Phase 3 first posted: Hoffmann-La Roche, Ipatasertib + Paclitaxel (NCT03337724)
- 2017-10-30Results posted on the registry: Merck Sharp & Dohme LLC, dalotuzumab + MK-0752 (NCT01243762)
- 2017-09-05Results posted on the registry: National Cancer Institute (NCI), Akt Inhibitor MK2206 (NCT01307631)
- 2017-08-30Also stopped (terminated): National Cancer Institute (NCI), Akt Inhibitor MK2206 (NCT01319539)
- 2017-08-01Results posted on the registry: National Cancer Institute (NCI), Akt Inhibitor MK2206 (NCT01319539)
- 2017-06-07Results posted on the registry: National Cancer Institute (NCI), Akt Inhibitor MK2206 + Everolimus (NCT01239342)
- 2017-05-30Results posted on the registry: National Cancer Institute (NCI), Akt Inhibitor MK2206 (NCT01802320)
- 2017-04-07Results posted on the registry: National Cancer Institute (NCI), Akt Inhibitor MK2206 (NCT01481129)
- 2017-03-07Phase 3 first posted: Hoffmann-La Roche, Ipatasertib + Abiraterone (NCT03072238)
- 2016-10-17Results posted on the registry: National Cancer Institute (NCI), Akt Inhibitor MK2206 + Erlotinib Hydrochloride (NCT01294306)
- 2016-10-06Also stopped (withdrawn): GlaxoSmithKline, Afuresertib + Enzalutamide (NCT02380313)
- 2016-06-28Results posted on the registry: National Cancer Institute (NCI), Akt Inhibitor MK2206 + Bendamustine Hydrochloride (NCT01369849)
- 2016-06-24Results posted on the registry: National Cancer Institute (NCI), Akt Inhibitor MK2206 (NCT01283035)
- 2016-05-25Results posted on the registry: AstraZeneca, AZD5363 + AZD5363 (NCT01895946)
- 2016-05-04Also stopped (terminated): Novartis, Afuresertib + Carfilzomib (NCT02235740)
- 2016-04-15Results posted on the registry: National Cancer Institute (NCI), Akt Inhibitor MK2206 (NCT01425879)
- 2016-03-28Results posted on the registry: Genentech, Inc., Ipatasertib + Cobimetinib (NCT01562275)
- 2016-03-10Also stopped (withdrawn): Dana-Farber Cancer Institute, MK-2206 (NCT01249105)
- 2016-03-09Results posted on the registry: National Cancer Institute (NCI), Akt Inhibitor MK2206 + Fluorouracil (NCT01658943)
- 2016-02-18Results posted on the registry: Memorial Sloan Kettering Cancer Center, MK-2206 (NCT01169649)
- 2016-02-12Results posted on the registry: National Cancer Institute (NCI), Akt Inhibitor MK2206 (NCT01277757)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision